FNY Partners Fund’s Impax Laboratories, Inc. IPXL Stock Holding History

FNY Partners Fund’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,500	Closed	-$91K	–	693
2017 Q3	$91K	Buy	+4,500	New	+$86K	0.02%	240
2017 Q2	–	Sell	-6,000	Closed	-$75K	–	1402
2017 Q1	$75K	Buy	6,000 +2,000	+50%	+$24.2K	0.01%	596
2016 Q4	$53	Buy	+4,000	New	+$68.4K	﹤0.01%	292

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FNY Partners Fund's IPXL Position: Q4 2017 in Review

FNY Partners Fund sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 4,500 shares — an estimated $91K sold.

FNY Partners Fund first reported a position in IPXL in Q4 2016 and held it in 3 quarters. The position peaked at $91K in Q3 2017. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

FNY Partners Fund reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
FNY Partners Fund sold 4,500 Impax Laboratories, Inc. shares in Q4 2017, an estimated $91K.
FNY Partners Fund first reported a position in Impax Laboratories, Inc. in Q4 2016 and held it in 3 quarters.
FNY Partners Fund's Impax Laboratories, Inc. position peaked at $91K in Q3 2017.
200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on FNY Partners Fund's 13F filing for Q4 2017, filed 24 Jan 2018.